Industry Interest in Sangamo’s Delivery Platform Intensifies Amid Financial Struggles Sangamo’s third major licensing deal for its STAC-BBB technology, this time with Eli Lilly, highlights growing pharmaceutical interest in advanced gene therapy delivery systems. Despite recent revenue declines and negative earnings, the company’s partnerships with Lilly, Genentech, and Astellas could provide critical financial lifelines and strategic momentum.783